Galunisertib

N/A

Report date: 2026/02/18 20:02:09
NME

Base Information

Drug NameGalunisertib
Drug Alias NameGalunisertibum加卢色替加尼舍替LY-2157299
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTransforming growth factor beta receptor 1 inhibitors
TargetsTransforming growth factor beta receptor 1
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursMyelodysplastic Syndromes +[20] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[18] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesGipfel Life Sciences GmbHThe Netherlands Cancer InstituteEli Lilly And Company +[7] 
Inactive CompaniesWeill Medical College of Cornell University
Active IndicationsAmyotrophic Lateral SclerosisProstatic NeoplasmsLiver Neoplasms +[11] 
Inactive IndicationsMetastatic breast cancerSolid tumoursMyelodysplastic Syndromes +[9] 

Other Information

ATC CodeN/A
Related LinksKEGG